exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088009 RNA Name: hsa-miR-302d-3p RNA Type: miRNA Chromosome: chr4 Starnd: - Coordinate: Start Site(bp): 112648006 End Site(bp): 112648028 External Links: hsa-miR-302d-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand POLR3G chr5 90471748 90514557 + RPL27 chr17 42998273 43002959 + MSL1 chr17 40121971 40136917 + MGLL chr3 127689062 128052190 - WASF3 chr13 26557683 26688948 + CCNE1 chr19 29811991 29824312 + PPIB chr15 64155812 64163205 - CDK6 chr7 92604921 92836594 - CLOCK chr4 55427903 55546909 - QRICH1 chr3 49029707 49094363 - FBXO5 chr6 152970519 152983579 - VPS35 chr16 46656132 46689518 - PXYLP1 chr3 141228726 141367753 + ATP6V1C1 chr8 103021063 103073051 + FYCO1 chr3 45917899 45995824 - TXNIP chr1 145992435 145996579 - KDM4B chr19 4969113 5153598 + PNPLA8 chr7 108470417 108569666 - AMPD2 chr1 109616104 109632053 + MMD chr17 55392622 55421924 - ZNF608 chr5 124636913 124748807 - PLAGL2 chr20 32192504 32207743 - EPHX1 chr1 225810092 225845563 + COPS5 chr8 67043079 67083783 - MRPS6 chr21 34073224 34143034 + RIT1 chr1 155897808 155911404 - HNRNPH2 chrX 101408222 101414133 + BCLAF1 chr6 136256627 136289851 - BTN3A1 chr6 26402237 26415208 + COL4A2 chr13 110305812 110513209 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000943 chr19 47421744 47440665 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC011503.2 chr19 23927788 23929287 + AL049840.4 chr14 103694516 103695050 - ARHGAP27P1-BPTFP1-KPNA2P3 chr17 64749663 64781707 - FGD5-AS1 chr3 14920347 14948424 - MIR17HG chr13 91347820 91354579 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - SNHG16 chr17 76557764 76565348 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.